Bristol-Myers Squibb (BMY) Presents New Long-term Data from the EMERGENT Program Evaluating COBENFY
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/14/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Bristol Myers Squibb Presents New Long-term Data from the EMERGENT Program Evaluating COBENFY™ (xanomeline and trospium chloride) in Adults with Schizophrenia at Psych Congress 2024
October 31, 2024 4:16 PM EDTLong-term treatment with COBENFY was associated with continued improvements in symptoms of schizophrenia, demonstrating maintenance of effect
COBENFY was generally well tolerated over 52 weeks with a side effect profile consistent with prior trials of COBENFY in schizophrenia
In-trial qualitative interviews found that a majority of participants treated with COBENFY in the long-term EMERGENT-5 trial reported Quality of Life improvements across physical, social, emotional, and role functioning
PRINCETON, N.J.--(BUSINESS... More
